搜索结果

Search Results for " c-mpl "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Species：

Expression System：

Tag：

Cat. No.	Product Name	Species	Expression System
TMPY-06863	C-MPL Protein, Mouse, Recombinant (His) c-mpl,MPL proto-oncogene...	Mouse	HEK293 Cells
	C-MPL Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 52.64 kDa and the accession number is Q08351-1.
TMPY-06797	C-MPL Protein, Human, Recombinant (His) MPL proto-oncogene, thrombopoietin rec...	Human	HEK293 Cells
	C-MPL Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 54 kDa and the accession number is P40238-1.
TMPK-00494	C-MPL Protein, Cynomolgus, Recombinant (His) TPO-R,MPLV,K12,CD110,MPL,c	Cynomolgus	HEK293 Cells
	C-MPL Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 53.48 kDa and the accession number is A0A2K5UGC7.
TMPK-00877	C-MPL Protein, Human, Recombinant (aa 26-491, His) MPL,c-Mpl,CD110,TPO-R,K1...	Human	HEK293 Cells
	C-MPL Protein, Human, Recombinant (aa 26-491, His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 53.6 kDa and the accession number is P40238-1.
TMPK-00940	C-MPL Protein, Mouse, Recombinant (aa 26-482, His) MPL,c-Mpl,CD110,TPO-R,	Mouse	HEK293 Cells
	C-MPL Protein, Mouse, Recombinant (aa 26-482, His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 52.3 kDa and the accession number is Q08351-1.
TMPJ-00235	TPO Protein, Human, Recombinant (His) Megakaryocyte growth and development facto...	Human	HEK293 Cells
	Thrombopoietin (TPO) is a glycoprotein hormone which belongs to the EPO/TPO family. It produced by the liver and kidney which regulates the production of platelets. TPO stimulates the production and differentiation of megakaryocytes, the bone marrow cells that bud off large numbers of platelets. Lineage-specific cytokine affects the proliferation and maturation of megakaryocytes from their committed progenitor cells. It acts at a late stage of megakaryocyte development. It may be the major physi...
TMPY-05423	C-MPL Protein, Rat, Recombinant (hFc) MPL proto-oncogene, thrombopoietin rec...	Rat	HEK293 Cells
	C-MPL Protein, Rat, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 80.7 kDa and the accession number is A0A1W2Q6N1.
TMPY-03421	C-MPL Protein, Rat, Recombinant (His) MPL proto-oncogene, thrombopoietin rec...	Rat	Baculovirus Insect Cells
	C-MPL Protein, Rat, Recombinant (His) is expressed in Baculovirus insect cells with His tag. The predicted molecular weight is 55.1 kDa.
TMPK-01450	HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01456	HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi) KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01451	HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi) NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.